Biopharma Quarterly Dealmaking Statistics, Q3 2016

A look at financing, M&A and alliance activity July–September 2016

In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.

IV1610_Calendar_1200X675

Third-quarter 2016 biopharma financing totaled $7.4 billion, a 54% increase over Q2’s $4.8 billion. Follow-on public offerings were again the lead financing vehicle, bringing in $3.36 billion – close to half of the aggregate amount raised – led by BioMarin Pharmaceutical Inc.’s $714 million August FOPO [See Deal], along with eight other $100 million-plus offerings. (See Exhibit 1.) The orphan disease-focused biotech will use the proceeds for continued clinical trials of its candidates for various rare genetic blood, metabolic and neuro diseases mostly affecting children. It already has five approved products: Vimizim (elosulfase alpha) for Morquio A syndrome, Naglazyme (galsulfase) for mucopolysaccharidosis VI (MPS VI), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Aldurazyme (laronidase) for MPS I, and Firdapse (amifampridine phosphate) for Lambert-Eaton myasthenic syndrome (LEMS) in adults.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo